Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review
Abstract Pulmonary arterial hypertension‐targeted therapies in portopulmonary hypertension (PoPH) are scarce, let alone for patients with chronic liver failure (CLF) and hepatopulmonary syndrome (HPS). A 48‐year male was admitted to the hospital because of cirrhosis for 18 years, systemic oedema, an...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.14431 |
| _version_ | 1797770735970680832 |
|---|---|
| author | Niuniu Li Qiang Wu Juan Meng Cheng Feng Siwei Jiang Meixia Chen Wenhui Xu Fei Wang Yifan Zhang Juncai Liu Cheng Xu Gaolin Liu Hong Gao |
| author_facet | Niuniu Li Qiang Wu Juan Meng Cheng Feng Siwei Jiang Meixia Chen Wenhui Xu Fei Wang Yifan Zhang Juncai Liu Cheng Xu Gaolin Liu Hong Gao |
| author_sort | Niuniu Li |
| collection | DOAJ |
| description | Abstract Pulmonary arterial hypertension‐targeted therapies in portopulmonary hypertension (PoPH) are scarce, let alone for patients with chronic liver failure (CLF) and hepatopulmonary syndrome (HPS). A 48‐year male was admitted to the hospital because of cirrhosis for 18 years, systemic oedema, and chest distress after exercise for 1 week. He was diagnosed with CLF, PoPH, and HPS. After 7 weeks of macitentan treatment, the patient's activity tolerance, pulmonary artery systolic pressure, arterial partial pressure of oxygen (PaO2), cTNI, and NT‐proBNP changes indicated gradual recovery, without hepatic safety concerns. This case indicated that administering macitentan in patients diagnosed as PoPH (with CLF and HPS) may be efficient and safe enough in a clinical setting. |
| first_indexed | 2024-03-12T21:26:28Z |
| format | Article |
| id | doaj.art-5a7acfabf0454c169c05bb6f296b21d3 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-03-12T21:26:28Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-5a7acfabf0454c169c05bb6f296b21d32023-07-28T06:30:48ZengWileyESC Heart Failure2055-58222023-08-011042718272110.1002/ehf2.14431Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature reviewNiuniu Li0Qiang Wu1Juan Meng2Cheng Feng3Siwei Jiang4Meixia Chen5Wenhui Xu6Fei Wang7Yifan Zhang8Juncai Liu9Cheng Xu10Gaolin Liu11Hong Gao12Department of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaDepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaDepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaDepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaDepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaDepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaDepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaDepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaDepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaDepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaDepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaWashington University in St. Louis St. Louis USADepartment of Geriatric Medicine Shenzhen Third People's Hospital Shenzhen ChinaAbstract Pulmonary arterial hypertension‐targeted therapies in portopulmonary hypertension (PoPH) are scarce, let alone for patients with chronic liver failure (CLF) and hepatopulmonary syndrome (HPS). A 48‐year male was admitted to the hospital because of cirrhosis for 18 years, systemic oedema, and chest distress after exercise for 1 week. He was diagnosed with CLF, PoPH, and HPS. After 7 weeks of macitentan treatment, the patient's activity tolerance, pulmonary artery systolic pressure, arterial partial pressure of oxygen (PaO2), cTNI, and NT‐proBNP changes indicated gradual recovery, without hepatic safety concerns. This case indicated that administering macitentan in patients diagnosed as PoPH (with CLF and HPS) may be efficient and safe enough in a clinical setting.https://doi.org/10.1002/ehf2.14431Hepatopulmonary syndromeLiver failureMacitentanPortopulmonary hypertension |
| spellingShingle | Niuniu Li Qiang Wu Juan Meng Cheng Feng Siwei Jiang Meixia Chen Wenhui Xu Fei Wang Yifan Zhang Juncai Liu Cheng Xu Gaolin Liu Hong Gao Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review ESC Heart Failure Hepatopulmonary syndrome Liver failure Macitentan Portopulmonary hypertension |
| title | Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review |
| title_full | Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review |
| title_fullStr | Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review |
| title_full_unstemmed | Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review |
| title_short | Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review |
| title_sort | macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome a case report and literature review |
| topic | Hepatopulmonary syndrome Liver failure Macitentan Portopulmonary hypertension |
| url | https://doi.org/10.1002/ehf2.14431 |
| work_keys_str_mv | AT niuniuli macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT qiangwu macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT juanmeng macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT chengfeng macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT siweijiang macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT meixiachen macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT wenhuixu macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT feiwang macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT yifanzhang macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT juncailiu macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT chengxu macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT gaolinliu macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview AT honggao macitentantreatmentofportopulmonaryhypertensionwithhepatopulmonarysyndromeacasereportandliteraturereview |